BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 35922951)

  • 1. [Treatment strategy for Philadelphia chromosome-positive acute lymphoblastic leukemia in children].
    Shimada H
    Rinsho Ketsueki; 2022; 63(7):799-804. PubMed ID: 35922951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allogeneic Hematopoietic Stem Cell Transplantation, Especially Haploidentical, May Improve Long-Term Survival for High-Risk Pediatric Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in the Tyrosine Kinase Inhibitor Era.
    Xue YJ; Cheng YF; Lu AD; Wang Y; Zuo YX; Yan CH; Wu J; Sun YQ; Suo P; Chen YH; Chen H; Jia YP; Liu KY; Han W; Xu LP; Zhang LP; Huang XJ
    Biol Blood Marrow Transplant; 2019 Aug; 25(8):1611-1620. PubMed ID: 30537550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discontinuation of Maintenance Tyrosine Kinase Inhibitors in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia outside of Transplant.
    Samra B; Kantarjian HM; Sasaki K; Alotaibi AS; Konopleva M; O'Brien S; Ferrajoli A; Garris R; Nunez CA; Kadia TM; Short NJ; Jabbour E
    Acta Haematol; 2021; 144(3):285-292. PubMed ID: 33238261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Jeha S; Coustan-Smith E; Pei D; Sandlund JT; Rubnitz JE; Howard SC; Inaba H; Bhojwani D; Metzger ML; Cheng C; Choi JK; Jacobsen J; Shurtleff SA; Raimondi S; Ribeiro RC; Pui CH; Campana D
    Cancer; 2014 May; 120(10):1514-9. PubMed ID: 24501014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of tyrosine kinase inhibitors on allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Zhang Y; Feng S
    Leuk Res; 2021 Oct; 109():106647. PubMed ID: 34325192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prophylactic or preemptive tyrosine kinase inhibitor therapy after allogeneic hematopoietic cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Nakasone H
    Int J Hematol; 2023 Aug; 118(2):183-192. PubMed ID: 36807259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic approach and outcome of children with Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors: An SFCE retrospective study.
    Aubert L; Petit A; Bertrand Y; Ray-Lunven AF; Angoso M; Pluchart C; Millot F; Saultier P; Cheikh N; Pellier I; Plantaz D; Sirvent A; Thouvenin-Doublet S; Valduga J; Plat G; Rialland F; Henry C; Esvan M; Gandemer V
    Pediatr Blood Cancer; 2022 Feb; 69(2):e29441. PubMed ID: 34854546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tyrosine kinase inhibitor use in pediatric Philadelphia chromosome-positive acute lymphoblastic anemia.
    Hunger SP
    Hematology Am Soc Hematol Educ Program; 2011; 2011():361-5. PubMed ID: 22160058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does Post-Transplant Maintenance Therapy With Tyrosine Kinase Inhibitors Improve Outcomes of Patients With High-Risk Philadelphia Chromosome-Positive Leukemia?
    DeFilipp Z; Langston AA; Chen Z; Zhang C; Arellano ML; El Rassi F; Flowers CR; Kota VK; Al-Kadhimi Z; Veldman R; Jillella AP; Lonial S; Waller EK; Khoury HJ
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16(8):466-471.e1. PubMed ID: 27297665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatments for Philadelphia chromosome-positive acute lymphoblastic leukemia in the tyrosine kinase inhibitor era].
    Dobashi N
    Rinsho Ketsueki; 2020; 61(9):1227-1235. PubMed ID: 33162520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T-cell-rich HLA-haploidentical hematopoietic stem cell transplantation for relapsed/refractory pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia without posttransplant tyrosine kinase inhibitor therapy.
    Sano H; Mochizuki K; Akaihata M; Kobayashi S; Ohto H; Kikuta A
    Pediatr Blood Cancer; 2017 Mar; 64(3):. PubMed ID: 27781393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ph+ ALL in 2022: is there an optimal approach?
    Wieduwilt MJ
    Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):206-212. PubMed ID: 36485090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allogeneic Stem Cell Transplantation versus Tyrosine Kinase Inhibitors Combined with Chemotherapy in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
    Wang J; Jiang Q; Xu LP; Zhang XH; Chen H; Qin YZ; Ruan GR; Jiang H; Jia JS; Zhao T; Liu KY; Jiang B; Huang XJ
    Biol Blood Marrow Transplant; 2018 Apr; 24(4):741-750. PubMed ID: 29247779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes of Tyrosine Kinase Inhibitors Maintenance Therapy with or without Allogeneic Hematopoietic Stem Cell Transplantation in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia in First Complete Remission: A Systematic Review and Meta-Analysis.
    Shahzad M; Hussain A; Tariq E; Anwar I; Faisal MS; Syed L; Karam A; Chaudhary SG; Ahmed N; Bansal R; Khurana S; Singh AK; Byrd KP; Hematti P; Abhyankar SH; McGuirk JP; Mushtaq MU
    Clin Lymphoma Myeloma Leuk; 2023 Mar; 23(3):178-187. PubMed ID: 36682989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
    Abou Dalle I; Jabbour E; Short NJ; Ravandi F
    Curr Treat Options Oncol; 2019 Jan; 20(1):4. PubMed ID: 30675645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of allogeneic hematopoietic stem cell transplantation and TKI combined with chemotherapy for adult philadelphia chromosome positive acute lymphoblastic leukemia: a systematic review and meta-analysis.
    Zeng Q; Xiang B; Liu Z
    Cancer Med; 2021 Dec; 10(24):8741-8753. PubMed ID: 34761879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Philadelphia Chromosome Positive and Philadelphia-Like Acute Lymphoblastic Leukemia in Children and Adolescents: Current Management, Controversies and Emerging Concepts.
    Ganguly S; Sasi A; Pushpam D; Bakhshi S
    Indian J Pediatr; 2024 Jan; 91(1):37-46. PubMed ID: 37632689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation between deletion of the CDKN2 gene and tyrosine kinase inhibitor resistance in adult Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Xu N; Li YL; Li X; Zhou X; Cao R; Li H; Li L; Lu ZY; Huang JX; Fan ZP; Huang F; Zhou HS; Zhang S; Liu Z; Zhu HQ; Liu QF; Liu XL
    J Hematol Oncol; 2016 Apr; 9():40. PubMed ID: 27090891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A position statement of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
    Giebel S; Czyz A; Ottmann O; Baron F; Brissot E; Ciceri F; Cornelissen JJ; Esteve J; Gorin NC; Savani B; Schmid C; Mohty M; Nagler A
    Cancer; 2016 Oct; 122(19):2941-51. PubMed ID: 27309127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relapse Prevention with Tyrosine Kinase Inhibitors after Allogeneic Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblast Leukemia: A Systematic Review.
    Warraich Z; Tenneti P; Thai T; Hubben A; Amin H; McBride A; Warraich S; Hannan A; Warraich F; Majhail N; Kalaycio M; Anwer F
    Biol Blood Marrow Transplant; 2020 Mar; 26(3):e55-e64. PubMed ID: 31557532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.